» Articles » PMID: 18381904

Age of Methylphenidate Treatment Initiation in Children with ADHD and Later Substance Abuse: Prospective Follow-up into Adulthood

Overview
Journal Am J Psychiatry
Specialty Psychiatry
Date 2008 Apr 3
PMID 18381904
Citations 105
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Animal studies have shown that age at stimulant exposure is positively related to later drug sensitivity. The purpose of this study was to examine whether age at initiation of stimulant treatment in children with attention deficit hyperactivity disorder (ADHD) is related to the subsequent development of substance use disorders.

Method: The authors conducted a prospective longitudinal study of 176 methylphenidate-treated Caucasian male children (ages 6 to 12) with ADHD but without conduct disorder. The participants were followed up at late adolescence (mean age=18.4 years; retention rate=94%) and adulthood (mean age=25.3; retention rate=85%). One hundred seventy-eight comparison subjects also were included. All subjects were diagnosed by blinded clinicians. The Cox proportional hazards model included the following childhood predictor variables: age at initiation of methylphenidate treatment, total cumulative dose of methylphenidate, treatment duration, IQ, severity of hyperactivity, socioeconomic status, and lifetime parental psychopathology. Separate models tested for the following four lifetime outcomes: any substance use disorder, alcohol use disorder, non-alcohol substance use disorder, and stimulant use disorder. Other outcomes included antisocial personality, mood, and anxiety disorders.

Results: There was a significant positive relationship between age at treatment initiation and non-alcohol substance use disorder. None of the predictor variables accounted for this association. Post hoc analyses showed that the development of antisocial personality disorder explained the relationship between age at first methylphenidate treatment and later substance use disorder. Even when controlling for substance use disorder, age at stimulant treatment initiation was significantly and positively related to the later development of antisocial personality disorder. Age at first methylphenidate treatment was unrelated to mood and anxiety disorders.

Conclusions: Early age at initiation of methylphenidate treatment in children with ADHD does not increase the risk for negative outcomes and may have beneficial long-term effects.

Citing Articles

Adolescents' Use of Medications for Attention-Deficit/Hyperactivity Disorder and Subsequent Risk of Nonmedical Stimulant Use.

McCabe V, Veliz P, Wilens T, Schepis T, Pasman E, Evans-Polce R J Adolesc Health. 2024; 75(1):188-191.

PMID: 38483378 PMC: 11405061. DOI: 10.1016/j.jadohealth.2024.01.024.


Is age of onset and duration of stimulant therapy for ADHD associated with cocaine, methamphetamine, and prescription stimulant misuse?.

McCabe S, Figueroa O, McCabe V, Schepis T, Schulenberg J, Veliz P J Child Psychol Psychiatry. 2023; 65(1):100-111.

PMID: 37062713 PMC: 10852992. DOI: 10.1111/jcpp.13807.


Identification and treatment of individuals with attention-deficit/hyperactivity disorder and substance use disorder: An expert consensus statement.

Young S, Abbasian C, Al-Attar Z, Branney P, Colley B, Cortese S World J Psychiatry. 2023; 13(3):84-112.

PMID: 37033892 PMC: 10075023. DOI: 10.5498/wjp.v13.i3.84.


Type of medication therapy for ADHD and stimulant misuse during adolescence: a cross-sectional multi-cohort national study.

Schepis T, Werner K, Figueroa O, McCabe V, Schulenberg J, Veliz P EClinicalMedicine. 2023; 58:101902.

PMID: 36969344 PMC: 10036501. DOI: 10.1016/j.eclinm.2023.101902.


Age-related clinical characteristics of children and adolescents with ADHD.

De Rossi P, DAiello B, Pretelli I, Menghini D, Di Vara S, Vicari S Front Psychiatry. 2023; 14:1069934.

PMID: 36778635 PMC: 9911799. DOI: 10.3389/fpsyt.2023.1069934.


References
1.
Lambert N, Hartsough C . Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil. 1998; 31(6):533-44. DOI: 10.1177/002221949803100603. View

2.
Brandon C, Marinelli M, Baker L, White F . Enhanced reactivity and vulnerability to cocaine following methylphenidate treatment in adolescent rats. Neuropsychopharmacology. 2001; 25(5):651-61. DOI: 10.1016/S0893-133X(01)00281-0. View

3.
Gittelman R, Mannuzza S, Shenker R, Bonagura N . Hyperactive boys almost grown up. I. Psychiatric status. Arch Gen Psychiatry. 1985; 42(10):937-47. DOI: 10.1001/archpsyc.1985.01790330017002. View

4.
Biederman J, Monuteaux M, Mick E, Spencer T, Wilens T, Silva J . Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med. 2006; 36(2):167-79. DOI: 10.1017/S0033291705006410. View

5.
Gittelman-Klein R, Klein D, Katz S, Saraf K, Pollack E . Comparative effects of methylphenidate and thioridazine in hyperkinetic children. I. Clinical results. Arch Gen Psychiatry. 1976; 33(10):1217-31. DOI: 10.1001/archpsyc.1976.01770100079008. View